Medicenna Doses First Patient in MDNA11 Phase 1/2 ABILITY Study [Financial Post (Toronto, Ontario, Canada)]
Medicenna Therapeutics Corp. - Common Shares (MDNA)
Company Research
Source: Financial Post
— Preliminary update on safety, PK/PD, and biomarker data expected by year-end 2021 — Preliminary efficacy readouts from study expected over the course of 2022 TORONTO and HOUSTON, Sept. 14, 2021 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the initiation of dosing of patients in the Phase 1/2 ABILITY ( A B eta-only IL I mmuno T herap Y ) study of MDNA11, the Company's selective, long-acting and novel IL-2 super-agonist. The study is designed to assess the safety, PK, PD, and anti-tumor activity of various doses of intravenously administered MDNA11 in patients with advanced solid tumors and includes an MDNA11 monotherapy arm, as well as a combination arm designed to evaluate MDNA11 with a checkpoint inhibitor. “Dosing the first patient with MDNA11 in the ABILITY study is a major step towards demonstrating MDNA11's potential in the clinic as a differentiated an
Show less
Read more
Impact Snapshot
Event Time:
MDNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MDNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MDNA alerts
High impacting Medicenna Therapeutics Corp. - Common Shares news events
Weekly update
A roundup of the hottest topics